# Organ Transplantation Market

> Organ Transplantation Market Research Report By Type Of Organ (Heart, Kidney, Others), By Products (Organ Preservation Solutions, Transplant Diagnostics, Tissue Products), By Type Of Transplant (Autograft, Allograft And Others), By Treatment (Analgesic, Immunosuppressant And Other), By End Users (Hospitals, Transplant Centers And Other) - Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.33%
- **2024:** $ 7.99 Billion
- **2025:** $ 8.66 Billion
- **2035:** $ 19.27 Billion
- **Key Players:** Companies such as United Therapeutics Corporation (US), AbbVie Inc. (US), Astellas Pharma Inc. (JP), Novartis AG (CH), Pfizer Inc. (US), Bristol-Myers Squibb Company (US), Hoffmann-La Roche Ltd (CH), Medtronic plc (IE), TransMedics Group, Inc. (US) are some of the major participants in the global market.

**Report ID:** MRFR/Pharma/0410-HCR · **Pages:** 80 · **Author:** Rahul Gotadki · **Last Updated:** June 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/organ-transplantation-market-915

---

## Market Summary

## **Organ Transplantation Market Overview**

Organ Transplantation Market Size was valued at USD 7.3 billion in 2023 and is projected to grow from USD 7.99 Billion in 2024 to USD 15.16 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.33% during the forecast period (2024 - 2032). The main market drivers boosting market expansion are the rising need for cutting-edge tissue transplant goods and organ transplants to cure organ failure.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

An organ or living tissue can be implanted in another body or part of the same body through the medical technique known as transplantation. The global growth in the need for organ transplants may be related to a spike in the number of severe illnesses, which in turn causes an upsurge in organ failures. 

For instance, diabetes and elevated blood pressure are among the leading causes of failure of the kidneys, in which transplants of kidneys or dialysis are the only options for therapy to keep a patient alive. One of the major reasons driving market expansion is the increased demand for these operations and the introduction of fresh solutions for avoiding the breakdown of these procedures.

Additionally, several government and non-government organizations are assisting in raising awareness of the significance of organ donation. Over the years, the market has seen a lot of strategic alliances. The great need for organ transplantation has resulted from increased organ failure instances. 

Numerous significant businesses consistently focus on expanding their product portfolios to increase the number of transplantations performed through partnerships. One significant aspect predicted to drive the global transplantation market growth is a significant increase in the number of transplants performed. Chronic illnesses like cancer, [renal disease](../../../reports/renal-disease-market-3167), COPD, and lupus, which are becoming more common, typically cause significant tissue and organ damage. One of the most important growing factors for the world economy is the increase in organ failures.

Numerous reasons, such as blood loss, poisoning, drug addiction, severe trauma, leukemia, sepsis, and other acute diseases, are frequently blamed for organ failure. This has resulted from an enormous worldwide requirement for tissue and organ transplantation—including organs like the kidneys, liver, heart, and lungs. 

Globally, there is a substantial need for tissue and transplantation of organs, particularly for the kidney, heart, liver, and lungs. In addition, cutting-edge technologies are being used to overcome immunologic obstacles, including decellularization and recellularization, three-dimensional (3D) bioprinting, and interspecies organogenesis.

Additionally, most individuals in poor nations are ignorant of the options available for these surgeries, and many ineffective reimbursement practices exist. Organ failure can be brought on by a variety of factors, including poor eating habits, alcohol intake, inactivity, and drug usage.

In November 2023, nine technology start-ups were launched from Sastra University’s business incubators. One of them was a medical transplant box that can be 3D printed and connected to the Internet of Things (IoT). It weighs only five kilograms. This means drugs, blood samples, and other body fluids, including human organs, can be moved using drones, together with critical care supplies. Others were natural supplements for cows that increased milk yields, hazardous operation robots, and an automatic irrigation system called an e-toggle that is controlled remotely by farmers. 

These products were commissioned by Nidhi Bansal, who is Scientist G and Director at the Directorate of Technology Development Fund-Defence Research and Development Organisation.

TransMedics Group Inc., which manufactures medical devices used in organ transplantation therapy for end-stage liver failure patients, has announced its acquisition of assets and intellectual property associated with Bridge to Life’s Ex-Vivo Organ Support System (“EVOSS”) and LifeCradle Heart Preservation Transport System (“LifeCradle”). EVOSS specifically facilitates the transport of lungs and hearts during transplantation through warm perfusion, while LifeCradle focuses on cold perfusion for heart transplants. Through this deal, TransMedics aims to strengthen its product portfolio in relation to organ transplantation.

In October 2023, Out \ Look on Out of Home McVitie’s Launches True Originals Brand Platform comes from PML Group Marketing Executive Aaron Poole. The release of McVitie’s master brand campaign called ‘True Originals’ signals a gauntlet thrown down amongst biscuit brands. 

The intention, according to the marketing communication endeavor, is to assert that when people think about biscuits, they should consider McVitie’s as their first choice because it is marked by originality, hence the name “True Original.” Over more than 180 years, it has grown into one of the UKIE’s dominant businesses with a long history as the market leader. However, copycats have forced a shake-up in the snack aisle, and so the brand must build mental availability if it is to remain top of mind for biscuit buyers.

Once upon a time, in February 2023, there was physical retail. Then Bezos said, “Let there be Prime,” and there was two-day delivery. And we saw that it was good. Since then, customers have increasingly expected orders to be delivered quickly, correctly, and with full visibility throughout the process since this landmark moment nearly 20 years ago. 

However, the major hurdle has always been what’s called the last mile—the distance between where an order ends up at its final distribution hub and when it actually gets into a customer’s hands. It is not only the most expensive and problematic part of a product’s journey but also an area of logistics management that is seeing some of its most exciting developments taking place.

## **Organ Transplantation Market Trends**

One of the key factors driving the expansion of the market under study is the rising organ donation rate. The Association of Organ Procurement Organizations (AOPO) reported that more than 12,500 persons donated one or more organs in 2020, an increase of 6% from the year before. Deceased donors donated over 36,500 organs in 2020, an increase of nearly 2% from the previous year. Additionally, it stated that over the preceding seven years, more than 33,000 lives had been saved using organs from the deceased, surpassing those from the year before. 

Additionally, there were notable gains in DCD contributions, reaching more than 3,000 donors in 2020. Increased transplant diagnostic testing is required due to increased organ donation, which propels the market's expansion. Creating technologically sophisticated tissue products is one of the distinctive characteristics anticipated to fuel market expansion.  Organ development using human induced pluripotent stem cells is a current scientific endeavor. In addition, cutting-edge technologies are used to overcome immunologic obstacles, including three-dimensional (3D) bioprinting, decellularization and recellularization, and interspecies organogenesis. 

Leading manufacturers are concentrating on introducing cutting-edge tissue products to the market. For instance, AlloSource introduced the AlloMend Ultra-Thick Acellular Dermal Matrix (ADM) in August 2021 to provide cutting-edge cellular and tissue products to aid surgeons in healing their patients. Thus, incorporating such distinctive tools will significantly accelerate market expansion. Therefore, such medical circumstances related has enhanced the market CAGR of Organ Transplantation in recent years.

However, The most common causes of organ failure are severe trauma, leukemia, poisoning, drug addiction, blood loss, sepsis, and other acute disorders. ly, there is a very high need for tissue and organ transplantation, particularly for the kidney, liver, heart, and lungs. Organ failure is primarily brought on by unhealthy eating patterns, alcohol intake, inactivity, and drug usage is another factor driving the growth of the Organ Transplantation market revenue.

**Figure 1: Number of transplantation**

## **Organ Transplantation Market Segment Insights**

### **Organ Transplantation Product Insights**

The Organ Transplantation market segmentation, based on Product, includes tissue products, immunosuppressive drugs, preservation solutions, and others. The tissue products segment held the majority share in 2022, contributing around ~45% concerning the market revenue of Organ Transplantation. This is because the need for organ and tissue transplants is growing. A large population is now at risk of irreversible tissue damage due to the increased prevalence of diseases like diabetes, cancer, cardiovascular disease, renal disease, and Alzheimer's disease. This has increased the need for tissue transplantation, boosting the segment's revenue market growth for Organ Transplantation

### **Organ Transplantation Application Insights**

The Organ Transplantation market data has been bifurcated by Application into Organ Transplantation and Tissue Transplantation. The Tissue Transplantation segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. This is because the most frequent surgical procedures around the world involve replacing the skin, cornea, bones, heart valves, tendons, nerves, and veins. The demand for tissue products is anticipated to increase due to the rise in burn and accident cases. Spain reported 102,362 injury accidents, according to the European Road Safety Observatory study.

They are resulting in a demand for tissue transplants.

**Figure 2:  Organ Transplantation Market, by Application, 2023 & 2032 (USD Million)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Organ transplant Additionally, compared to Tissue Transplantation, minimally invasive Application is faster, safer, and needs less recovery time. Rising potential benefits such as less blood loss from Application, lower chance of muscle injury and infection, less postoperative discomfort, and faster recovery from degenerative disc disease, lumbar spinal stenosis, and ruptured disc Application are likely to drive sector growth throughout the projection period.

### **Organ Transplantation End User Insights**

Based on End Users, the market segmentation for Organ Transplantation has been segmented into Hospitals, Transplant Centers, and others. Hospitals held the most significant segment share in 2022, increasing the number of surgeries and medical procedures carried out in hospitals. Most hospitals have easier access to well-defined organ databases that can confirm the availability of requested organs, enabling quicker medical intervention fueling the segment's revenue rise.

The fastest-growing segment in the Organ Transplantation industry is transplant centers. Due to the increasing demand for advanced healthcare facilities and transplant centers are an excellent choice for older persons as they offer individualized care and reduce the need for frequent hospital visits. The danger of infections acquired in hospitals is also reduced by treatment in transplant centers.

**News:**

The first participant in the Phase 2 BESTOW trial, which is testing the effectiveness of tegoprubart in preventing organ rejection in kidney transplant recipients, has been dosed, according to Eledon Pharmaceuticals, Inc. About 120 people undergoing kidney transplantation in the US and other countries will be enrolled in BESTOW, a multicenter, two-arm, active comparator medical study, to compare the safety, pharmacokinetics, and effectiveness of the anti-CD40 ligand antibody tegoprubart to the calcineurin inhibitor tacrolimus. 

The study's main goal is to compare people treated with tegoprubart to those treated with tacrolimus regarding graft function at twelve months post-transplant, as determined by the estimated glomerular filtration rate (eGFR). Improvements in permanent patient and graft survival have been linked to better graft function as measured by eGFR.

### **Organ Transplantation Regional Insights**

By Region, the study provides market insights for Organ Transplantation into North America, Europe, Asia-Pacific, and the Rest of the World. In North America, the market of Organ Transplantation accounted for USD 3.06 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. Because of the ongoing development of novel transplantation goods for treatment, a well-developed healthcare system, and rising consumer spending on personal health. The strong presence of numerous large-scale biotechnology and medical device firms is also anticipated to fuel the market's revenue growth in North America.

Further, the significant countries studied in the market report for Organ Transplantation are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 3:  ORGAN TRANSPLANTATION MARKET SHARE BY REGION 2022 (%)**

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europe's Organ Transplantation market accounts for the second-largest market share The rise in these operations and the critical measures taken by various governments to enhance awareness of organ donation in the area can be credited with the expansion. Further, the Germany market of Organ Transplantation held the largest market share, and the UK market of Organ Transplantation was the fastest-growing market in the European region.

The Asia-Pacific Organ Transplantation Market is expected to grow at the fastest CAGR from 2024 to 2032. Growing number of chronic diseases and the increasing frequency of traffic accidents permanently destroy organs and necessitate replacing them with healthy organs to preserve the patient's life. The expansion of the Asia Pacific transplantation market's revenue is also driven by leading companies' ongoing improvements in transplantation technology in these nations. Moreover, the China market of Organ Transplantation held the largest market share, and the India market of Organ Transplantation was the fastest-growing market in the Asia-Pacific region.

### **Organ Transplantation Key Market Players & Competitive Insights**

Major industry players are investing a lot of money in R&D to broaden their product offerings, which will fuel further market expansion of the Organ Transplantation. Along with essential industry activities, including new product releases, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations, market participants are also undertaking various strategic initiatives to enhance their  footprint. Organ transplant industry competitors must provide affordable products to grow and thrive in a market that is becoming increasingly competitive.

Manufacturing locally to cut operational costs is one of the leading business methods manufacturers use in the worldwide organ transplantation industry to benefit customers and increase the market sector. In recent years, Organ Transplantation industry has provided medicine with some of the most significant benefits. The market of Organ Transplantation major player such as Natera Inc, NephroSant, and others are working to expand the market demand by investing in research and development activities.

With an emphasis on women's health, cancer, and organ health, Natera, Inc. is a clinical genetic testing business with headquarters in Austin, Texas. Natera specializes in non-invasive, cell-free DNA testing technologies. In September 2022, Prospera with Quantification, a cfDNA test for kidney rejection, was introduced by Natera Inc., one of the leading companies redefining healthcare via genetic and cell-free DNA (cfDNA) testing.

Also, A biotechnology business called NephroSant creates ground-breaking diagnostic instruments for the lifetime monitoring of kidney health and the early diagnosis of risk of kidney illness or injury.  In March 2022, The Evaluation of QSant for Underlying Allograft Rejection (AQUA) trial began with the recruitment of the first patient by a biotechnology company committed to accelerating the assessment of early kidney injury.

**Key Companies in the Organ Transplantation market includes**

### Organ Transplantation Market Industry Developments

- **Q1 2025: Organ transplants exceeded 48,000 in 2024; a 3.3 percent increase from the transplants performed in 2023** The United States performed 48,149 organ transplants in 2024, marking a 3.3% increase over 2023 and the highest annual total ever recorded, according to preliminary OPTN data.
- **Q1 2025: U.S. Organ Procurement Organizations Recovered Record Number of Organs in 2024 While Looming Federal Policies Jeopardize Patients** U.S. Organ Procurement Organizations recovered over 45,000 organs for transplantation in 2024, setting a new record and marking the 14th consecutive year of increased organ recovery.
- **Q1 2025: Organ transplants exceeded 48,000 in 2024; a 3.3 percent increase from the transplants performed in 2023** In 2024, 7,030 people became living organ donors in the U.S., including 476 donors aged 65 and older—a 14.2% increase over 2023 for this age group.
- **Q1 2025: U.S. Organ Procurement Organizations Recovered Record Number of Organs in 2024 While Looming Federal Policies Jeopardize Patients** AOPO announced its goal to reach 50,000 organs transplanted in 2026, emphasizing the need for federal policy alignment to maximize transplantation of every viable donated organ.
- **Q1 2025: More than 7,000 living donor transplants in 2024** Over 7,000 living donor transplants were performed in the U.S. in 2024, with most donors providing kidneys and an increasing number donating liver segments.
- **Q1 2025: More than 17,000 deceased donors in 2024** The U.S. saw more than 17,000 deceased organ donors in 2024, contributing to a record-breaking year for organ donation and transplantation.

## **Organ Transplantation Market Segmentation**

### **Organ Transplantation Type Outlook**

### **Organ Transplantation Application Outlook**

### **Organ Transplantation End User Outlook**

### **Organ Transplantation Regional Outlook**

## Market Drivers

### Government Initiatives and Funding

Government initiatives aimed at improving organ donation rates and transplantation services are playing a pivotal role in shaping the Organ Transplantation Market. Various countries are implementing policies that promote organ donation, including financial incentives for donors and their families. Additionally, increased funding for transplantation research and infrastructure development is enhancing the capabilities of healthcare systems to perform more transplants.
 
For instance, some governments have allocated millions in funding to support organ transplant programs, which has led to improved outcomes and increased transplant volumes. These initiatives not only bolster the Organ Transplantation Market but also ensure that more patients receive the life-saving transplants they need.
 

- According to World Bank Health Data, global health expenditure exceeds USD 9 trillion annually, reflecting strong government commitment toward healthcare infrastructure and advanced treatment programs. Increased public funding for transplant centers, donor awareness initiatives, and transplantation research continues to improve patient access and strengthen organ transplantation capabilities worldwide.

### Increasing Incidence of Organ Failure

The rising prevalence of chronic diseases such as diabetes and hypertension contributes significantly to the increasing incidence of organ failure. This trend is likely to drive the demand for organ transplantation procedures. According to recent statistics, the number of patients awaiting organ transplants continues to grow, with estimates suggesting that over 100,000 individuals are on waiting lists in various regions.
 
This situation underscores the urgent need for effective solutions within the Organ Transplantation Market, as healthcare systems strive to address the gap between organ supply and demand. As the population ages and lifestyle-related health issues become more common, the Organ Transplantation Market is poised for expansion, necessitating innovative approaches to organ procurement and transplantation.
 

- According to IHME, chronic kidney disease affected more than 850 million people globally in recent assessments. The growing prevalence of kidney failure and other chronic conditions continues to expand transplant waiting lists, creating sustained demand for organ transplantation services and supporting long-term market growth.

### Rising Public Awareness of Organ Donation

Public awareness campaigns regarding the importance of organ donation are gaining momentum, positively impacting the Organ Transplantation Market. Educational initiatives aimed at dispelling myths and misconceptions about organ donation are fostering a more informed public. As a result, there has been a noticeable increase in the number of registered organ donors.
 
Reports indicate that countries with robust awareness programs have seen donor registration rates rise by as much as 30%. This surge in donor registrations is crucial for addressing the organ shortage crisis and is likely to enhance the operational dynamics of the Organ Transplantation Market. The growing acceptance of organ donation as a life-saving measure is expected to further stimulate market growth.

### Advancements in Transplantation Technology

Technological innovations in the field of organ transplantation are transforming the landscape of the Organ Transplantation Market. Developments such as improved organ preservation techniques, enhanced surgical methods, and the use of artificial organs are becoming increasingly prevalent. For instance, the introduction of machine perfusion technology has shown promise in extending the viability of donor organs, thereby increasing the number of successful transplants.
 
Furthermore, the integration of artificial intelligence in matching donors with recipients is streamlining the transplantation process. These advancements not only enhance patient outcomes but also contribute to the overall growth of the Organ Transplantation Market, as they facilitate more efficient and effective transplant procedures.

### Ethical Considerations and Regulatory Frameworks

The evolving ethical considerations surrounding organ transplantation are influencing the regulatory frameworks that govern the Organ Transplantation Market. As the demand for organs rises, regulatory bodies are tasked with ensuring that organ procurement and transplantation processes are conducted ethically and transparently. This includes establishing guidelines for donor consent and equitable distribution of organs.
 
The implementation of stringent regulations is likely to enhance public trust in the organ transplantation system, thereby encouraging more individuals to consider becoming donors. As ethical standards continue to evolve, they will shape the operational landscape of the Organ Transplantation Market, ensuring that it remains aligned with societal values and expectations.

## Future Outlook

The Organ Transplantation Market size is projected to reach USD 1.824 Billion by 2035, growing at a CAGR of 8.33%, driven by technological advancements, increasing organ demand, and improved healthcare infrastructure.

**New opportunities:**

- Development of AI-driven organ matching software Expansion of telehealth services for pre- and post-transplant care Investment in bioprinting technologies for organ regeneration

By 2035, the market is expected to achieve substantial growth, enhancing global organ transplantation capabilities.

## Segment Insights

### By Product: Immunosuppressive Drugs (Largest) vs. Preservation Solutions (Fastest-Growing)

In the Organ Transplantation Market, the distribution of market share among different product segments is critical for understanding industry dynamics. Immunosuppressive drugs hold the largest market share of 49% due to their essential role in preventing organ rejection after transplantation. Tissue products also contribute significantly, followed by preservation solutions, which are gaining traction. This segment is bolstered by innovations in preservation technologies that ensure organ viability, reflecting shifting preferences among transplant centers who are keen on maximizing transplant success rates. The growth trends in this market indicate that while immunosuppressive drugs remain the dominant choice, preservation solutions are emerging as the fastest-growing segment. Increased awareness about improved preservation methods has motivated investment in research and development, bringing forth novel solutions that promise enhanced organ preservation techniques. The rise in transplant procedures globally also fuels the growth of both product segments, with a gradual shift toward adopting advanced preservation methods as a standard practice.

Novartis AG continues supporting transplant care through immunosuppressive therapies used across thousands of transplant recipients globally. Continuous innovation in anti-rejection medications has significantly improved long-term graft survival rates, reinforcing the dominant position of immunosuppressive drugs within the organ transplantation market.

### By Application: Organ Transplantation (Largest) vs. Tissue Transplantation (Fastest-Growing)

The organ transplantation market is primarily dominated by organ transplantation applications, which significantly overshadow tissue transplantation, accounting for the largest market share of 72%. This dominance can be attributed to the higher demand for organ transplants such as kidneys, livers, and hearts, which are critical for lifesaving treatment. While both segments play a crucial role in patient care, organ transplantation leads the way due to established protocols and societal awareness regarding the need for organ donation, thus securing a larger market share within the sector. On the other hand, tissue transplantation, while smaller in market share, is emerging rapidly, driven by increasing occurrences of soft tissue injuries and the expanding use of tissue grafts in surgical procedures. Factors such as improved technology for tissue preservation and processing are fueling this growth. As medical professionals become more adept at utilizing tissue transplants effectively, this segment is expected to witness significant advancement in the coming years, attracting a broader patient demographic and healthcare investments.

Pfizer Inc. supports transplant medicine through therapies that assist post-transplant patient management. Globally, more than 150,000 organ transplants are performed annually, highlighting the substantial demand for organ transplantation procedures and supporting the segment's leading market position.

### By End User: Hospitals (Largest) vs. Transplant Centers (Fastest-Growing)

In the Organ Transplantation Market, hospitals have established themselves as the largest end-user segment, accounting for 61%, owing to their comprehensive capabilities in handling complex transplant procedures and patient care. This dominance is supported by an extensive network providing surgical services and post-operative care, catering to a broad patient demographic. Meanwhile, transplant centers are gaining traction with their specialized focus, which appeals to a defined segment of patients requiring targeted transplantation services. Their contribution to the overall market share is gradually increasing as they gain recognition for their advanced methodologies and successful transplant outcomes.

Hoffmann-La Roche Ltd continues supporting transplant diagnostics and monitoring technologies used by major healthcare institutions worldwide. Hospitals perform the majority of complex transplant procedures due to comprehensive surgical infrastructure, multidisciplinary care teams, and advanced post-operative monitoring capabilities, reinforcing their leadership position in market demand.

## Regional Market Share Analysis

### North America : Leading Market for Transplants

North America is the largest market for organ transplantation, accounting for approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high demand for organ transplants, and supportive regulatory frameworks. The increasing prevalence of chronic diseases and the aging population are significant growth drivers, alongside initiatives to improve organ donation rates.

- According to CDC data, approximately 38.4 million Americans are living with diabetes, a major contributor to kidney failure and transplant demand. The growing chronic disease burden continues to support organ transplantation volumes, while advanced healthcare infrastructure strengthens patient access to transplant procedures across North America.

The United States is the primary contributor, with a robust network of transplant centers and a high number of transplant procedures performed annually. Key players such as United Therapeutics Corporation and AbbVie Inc. are actively involved in research and development, enhancing treatment options. The competitive landscape is characterized by innovation and collaboration among leading pharmaceutical companies, ensuring a steady supply of organ transplant solutions.

- Bristol Myers Squibb Company invests billions of dollars annually in research and development, supporting innovation across complex therapeutic areas. Continued investment in advanced healthcare solutions, combined with strong clinical research infrastructure, reinforces North America's leadership position in transplantation innovation and patient care.

### Europe : Emerging Market Dynamics

Europe is witnessing a growing organ transplantation market, holding approximately 30% of the global share. The region's growth is driven by increasing awareness of organ donation, advancements in transplant technologies, and supportive government policies. Countries like Germany and the UK are leading in transplant procedures, with regulatory bodies promoting organ donation initiatives to address the rising demand. Germany stands out as a leader in organ transplantation, supported by a well-established healthcare system and a network of transplant centers.

The competitive landscape includes major players like Novartis AG and Astellas Pharma Inc., which are focusing on innovative therapies and improving patient outcomes. The European market is characterized by collaboration among healthcare providers, regulatory agencies, and pharmaceutical companies to enhance organ transplant success rates.

- The European Medicines Agency (EMA) supports medicines regulation for over 450 million citizens across the European Union. Its robust regulatory framework facilitates the introduction of innovative therapies, strengthens patient safety standards, and supports continued advancement in transplantation treatment across Europe.

### Asia-Pacific : Rapidly Growing Market

Asia-Pacific is rapidly emerging as a significant player in the organ transplantation market, accounting for about 20% of the global share. The region's growth is fueled by increasing healthcare investments, rising awareness of organ donation, and advancements in medical technology. Countries like Japan and Australia are at the forefront, implementing policies to enhance organ donation rates and improve transplant outcomes.

Japan is particularly notable for its advanced healthcare system and innovative transplant procedures. The competitive landscape features key players such as Pfizer Inc. and Bristol-Myers Squibb Company, which are investing in research to develop new therapies. The presence of a growing number of transplant centers and collaborations among healthcare providers are further driving market growth in this region.

### Middle East and Africa : Emerging Market Potential

The Middle East and Africa region is gradually developing its organ transplantation market, currently holding about 5% of the global share. The growth is driven by increasing healthcare investments, rising awareness of organ donation, and government initiatives to improve healthcare infrastructure. Countries like South Africa and the UAE are leading efforts to enhance organ transplant programs and address the growing demand for transplants.

South Africa is a key player in the region, with established transplant centers and a focus on improving organ donation rates. The competitive landscape includes local and international players, with a growing emphasis on collaboration to enhance transplant success. The region's potential for growth is significant, as healthcare systems continue to evolve and adapt to meet the needs of patients requiring organ transplants.

## Competitive Benchmarking

The Organ Transplantation Market is characterized by a complex interplay of competitive dynamics, driven by increasing demand for organ transplants and advancements in medical technology. Key players such as United Therapeutics Corporation (US), AbbVie Inc. (US), and Novartis AG (CH) are strategically positioned to leverage innovation and partnerships to enhance their market presence. United Therapeutics Corporation (US) focuses on developing novel therapies for organ transplantation, while AbbVie Inc. (US) emphasizes its robust pipeline of immunosuppressive drugs.
 
Novartis AG (CH) is actively pursuing collaborations to expand its reach in the transplantation sector, indicating a collective strategy among these companies to shape a competitive environment that prioritizes innovation and patient outcomes. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the Organ Transplantation Market appears moderately fragmented, with several key players exerting influence over various segments.
 
This fragmentation allows for diverse strategies, as companies seek to differentiate themselves through specialized offerings and targeted regional expansions. In August 2025, United Therapeutics Corporation (US) announced a groundbreaking partnership with a leading biotechnology firm to develop a new class of organ preservation solutions. This strategic move is likely to enhance the viability of transplanted organs, potentially increasing transplant success rates and expanding the donor pool. Such innovations could significantly alter the landscape of organ transplantation, positioning United Therapeutics as a leader in this critical area.
 
In September 2025, AbbVie Inc. (US) launched a new immunosuppressive therapy specifically designed for kidney transplant patients. This product introduction not only strengthens AbbVie’s portfolio but also reflects its commitment to addressing unmet medical needs in transplantation. The strategic importance of this launch lies in its potential to improve patient outcomes and reduce the incidence of organ rejection, thereby solidifying AbbVie’s competitive edge in the market. In July 2025, Novartis AG (CH) entered into a strategic alliance with a prominent research institution to explore gene therapy applications in organ transplantation.
 
This collaboration signifies a forward-thinking approach, as gene therapy could revolutionize the way organ rejection is managed. The implications of this partnership may extend beyond immediate market gains, potentially leading to groundbreaking advancements in transplantation science. As of October 2025, current trends in the Organ Transplantation Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing operational efficiencies.
 
Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative therapies, and reliable supply chains. This shift underscores the importance of adaptability and forward-thinking strategies in navigating the complexities of the organ transplantation market.

## Recent News & Developments

- **Q1 2025: Organ transplants exceeded 48,000 in 2024; a 3.3 percent increase from the transplants performed in 2023** The United States performed 48,149 organ transplants in 2024, marking a 3.3% increase over 2023 and the highest annual total ever recorded, according to preliminary OPTN data.
- **Q1 2025: U.S. Organ Procurement Organizations Recovered Record Number of Organs in 2024 While Looming Federal Policies Jeopardize Patients** U.S. Organ Procurement Organizations recovered over 45,000 organs for transplantation in 2024, setting a new record and marking the 14th consecutive year of increased organ recovery.
- **Q1 2025: Organ transplants exceeded 48,000 in 2024; a 3.3 percent increase from the transplants performed in 2023** In 2024, 7,030 people became living organ donors in the U.S., including 476 donors aged 65 and older—a 14.2% increase over 2023 for this age group.
- **Q1 2025: U.S. Organ Procurement Organizations Recovered Record Number of Organs in 2024 While Looming Federal Policies Jeopardize Patients** AOPO announced its goal to reach 50,000 organs transplanted in 2026, emphasizing the need for federal policy alignment to maximize transplantation of every viable donated organ.
- **Q1 2025: More than 7,000 living donor transplants in 2024** Over 7,000 living donor transplants were performed in the U.S. in 2024, with most donors providing kidneys and an increasing number donating liver segments.
- **Q1 2025: More than 17,000 deceased donors in 2024** The U.S. saw more than 17,000 deceased organ donors in 2024, contributing to a record-breaking year for organ donation and transplantation.

## Report Scope

| MARKET SIZE 2024 | 7.99(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 8.656(USD Billion) |
| MARKET SIZE 2035 | 19.27(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.33% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | United Therapeutics Corporation (US), AbbVie Inc. (US), Astellas Pharma Inc. (JP), Novartis AG (CH), Pfizer Inc. (US), Bristol-Myers Squibb Company (US), Hoffmann-La Roche Ltd (CH), Medtronic plc (IE), TransMedics Group, Inc. (US) |
| Segments Covered | Type Of Organ, Products, Type Of Transplant, Treatment, End Users |
| Key Market Opportunities | Advancements in organ preservation techniques enhance transplant success rates and expand donor organ viability. |
| Key Market Dynamics | Technological advancements and regulatory changes are reshaping the competitive landscape of the organ transplantation market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Organ Transplantation Market by 2035?**
A: The Organ Transplantation Market is projected to reach a valuation of 19.27 USD Billion by 2035.

**Q: What was the market valuation of the Organ Transplantation Market in 2024?**
A: In 2024, the Organ Transplantation Market was valued at 7.99 USD Billion.

**Q: What is the expected CAGR for the Organ Transplantation Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Organ Transplantation Market during the forecast period 2025 - 2035 is 8.33%.

**Q: Which segments are included in the Organ Transplantation Market analysis?**
A: The Organ Transplantation Market analysis includes segments such as Tissue Products, Immunosuppressive Drugs, Preservation Solutions, and others.

**Q: What are the projected values for Immunosuppressive Drugs in the Organ Transplantation Market?**
A: The projected values for Immunosuppressive Drugs range from 3.0 USD Billion to 7.0 USD Billion.

**Q: Who are the key players in the Organ Transplantation Market?**
A: Key players in the Organ Transplantation Market include United Therapeutics Corporation, AbbVie Inc., and Novartis AG, among others.

**Q: What is the expected growth for the Organ Transplantation application segment by 2035?**
A: The Organ Transplantation application segment is expected to grow from 4.79 USD Billion to 11.56 USD Billion by 2035.

**Q: How do hospitals and transplant centers compare in terms of market valuation?**
A: In 2024, hospitals were valued at 3.5 USD Billion, while transplant centers were valued at 2.5 USD Billion.

**Q: What is the projected market size for Preservation Solutions by 2035?**
A: The projected market size for Preservation Solutions is expected to grow from 1.0 USD Billion to 2.5 USD Billion by 2035.

**Q: What trends are influencing the growth of the Organ Transplantation Market?**
A: Trends influencing the growth of the Organ Transplantation Market include advancements in immunosuppressive drugs and increasing demand for organ transplants.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/organ-transplantation-market-915*